secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2021-10-19T23:59:59+00:00
Accession:  0001607062-21-000431
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma engages Biotech Research Group for NR2F6 IP assessment at $25k total
--------------------------------------------------------------------------------

- Engaged BRG to perform a GAP assessment of CRO work on NR2F6 checkpoint pre-clinical protocols, raw data, and completion report.
- Total fee of $25,000 due immediately upon SOW signing; work to be completed by November 15, 2021.
- Deliverables include a gap assessment report and a regulatory strategy work package for NR2F6 IP.
- Scope of Work Order effective October 11, 2021, under existing Master Services Agreement dated May 12, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000431/0001607062-21-000431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000431/rgbp101821form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-21-000431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer